Multiple endogenous pathways

Multiple endogenous pathways is a non-specific pharmacological descriptor rather than a defined molecular target. It refers to the simultaneous modulation of various internal signaling cascades, such as metabolic, inflammatory, or homeostatic routes, by a single therapeutic intervention (Hopkins, A. L., 2008, Nature Chemical Biology). This term is frequently encountered in the study of polypharmacology or multi-target drugs, where the efficacy of a compound is derived from its interaction with several distinct proteins or receptors (Peters, J. U., 2013, Journal of Medicinal Chemistry). Because it does not correspond to a specific gene product or a unique biochemical structure, it cannot be validated using standard drug discovery assays like high-throughput screening or site-directed mutagenesis. For biotech analysts, this classification indicates a lack of mechanistic granularity, which often complicates the regulatory approval process and the identification of precise biomarkers. Consequently, Multiple endogenous pathways is considered an incorrect entry for a target-specific database as it lacks the necessary molecular specificity required for therapeutic development (National Institutes of Health, 2023, Target Validation Standards).

Not applicable as this is a descriptive term for a collection of biological processes rather than a single molecular target.